Effectiveness and safety of vernakalant in converting atrial fibrillation
ZHANG Bo
FU Xiao
CHENG Xiao-cheng
HU Guang-xin
CHEN Zhu
ZHANG Mei
CHEN Shao-jie
YIN Yue-hui
Abstract：Objective To review systematically the effectiveness and safety of vernakalant in converting atrial fibrillation (AF). Methods The databases of PubMed, Cochrane Library and CBM were retrieved for collecting perspective control studies about treatment of AF (or atrial flutter) were retrieved from Jan. 2000 to Jun. 2013. The studies were selected according to pre-set inclusion and exclusion criteria and then given quality reviews by using Jadad rating scale. The data was extracted by two independent researches from included studies and then given Meta-analysis by using Revman5.0 software. Results There were 7 trials met the inclusion criterion involving 1133 patients (668 in vernakalant group and 465 in control group). The results of Meta-analysis showed that conversion rate was higher in vernakalant group than that in control group (38.3% vs. 14.1%; OR=5.73; P<0.0001). The conversion rate reached 52.2%(95%CI:46.9%~57.4%) in the patients with new-onset AF and median conversion time was 11 min. The conversion rate was 8.3% (95%CI: 3.1%~13.6%) in the patients with persistent AF. Vernakalant had not significant effect on atrial flutter and the terminating rate was 2.6%only. Although it prolonged QRS duration and QT interval, vernakalant did not increase the risk of major cardiovascular adverse events during observation period. Conclusion The current evidence of evidence-based medicine shows that vernakalant is safe, effective and quick in converting AF.
Keywords：VernakalantAtrial fibrillationSystemic reviewing
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 6-9 )